Rare Cancer News & Clinical Trials » Trials - Gall Bladder Cancer

Feeds

3963 items (3963 unread) in 74 feeds

Acinar Cell Carcinoma (26 unread)

• Google - Acinar Cell Carcinoma (1 unread)
• PubMed - Acinar Cell Carcinoma (25 unread)
• Trial - Acinar Cell Carcinoma

Acinic Cell Carcinoma (29 unread)

• Google - Acinic Cell Carcinoma (1 unread)
• PubMed - Acinic Cell Carcinoma (28 unread)
• Trial - Acinic Cell Carcinoma

Adenoid Cystic Carcinoma (62 unread)

• Google - Adenoid Cystic Carcinoma (3 unread)
• PubMed - Adenoid Cystic Carcinoma (49 unread)
• Trial - Adenoid Cystic Carcinoma (10 unread)

Adrenal Gland Cancer (307 unread)

• Google - Adrenal Cancer
• Google - Adrenocortical Carcinoma (3 unread)
• PubMed - Adrenal Cancer (245 unread)
• PubMed - Adrenocortical Carcinoma (40 unread)
• Trial - Adrenal Cancer (13 unread)
• Trial - Adrenocortical Carcinoma (6 unread)

Ampulla Of Vater (30 unread)

• Google - Ampullary Cancer (1 unread)
• PubMed - Ampullary Cancer (29 unread)
• Trial - Ampullary Carcinoma

Anal Cancer (315 unread)

• Google - Anal Cancer (18 unread)
• PubMed - Anal Cancer (279 unread)
• Trial - Anal Cancers (18 unread)

Angiosarcoma (75 unread)

• Google - Angiosarcoma (9 unread)
• PubMed - Angiosarcoma (65 unread)
• Trial - Angiosarcoma (1 unread)

Appendix Cancer (71 unread)

• Google - Appendix Cancer (11 unread)
• PubMed - Appendix Cancer (55 unread)
• Trial - Appendix Cancer (5 unread)

Bile Duct Cancer (521 unread)

• Google - Bile Duct Cancer (8 unread)
• Google - Cholangiocarcinoma (6 unread)
• PubMed - Bile Duct Cancer (245 unread)
• PubMed - Cholangiocarcinoma (203 unread)
• Trial - Bile Duct Cancer (31 unread)
• Trial - Cholangiocarcinoma (28 unread)

Brain and CNS (709 unread)

• Google - Rare Brain Tumor (12 unread)
• Google - Rare CNS Tumor (8 unread)
• PubMed - Ganglioglioma (19 unread)
• PubMed - Rare Brain Tumor (199 unread)
• PubMed - Rare CNS Tumor (238 unread)
• Trial - Brain Tumor (138 unread)
• Trial - CNS Tumor (94 unread)
• Trial - Ganglioglioma (1 unread)

Carcinoid (104 unread)

• Google - Carcinoid (11 unread)
• PubMed - Carcinoid (83 unread)
• Trials - Carcinoid (10 unread)

Endocrine/Neuroendocrine (371 unread)

• Google - Merkel Cell Cancer (12 unread)
• Google - Neuroendocrine Tumor (13 unread)
• PubMed - Merkel Cell Cancer (42 unread)
• PubMed - Neuroendocrine Tumor (175 unread)
• Trial - Merkel Cell Cancer (10 unread)
• Trial - Neuroendocrine Cancers (119 unread)

Gall Bladder Cancer (127 unread)

• Google - Gall Bladder Cancer (22 unread)
• PubMed - Gall Bladder Cancer (94 unread)
• Trials - Gall Bladder Cancer (11 unread)

Hemangioendothelioma (29 unread)

• Google - Hemangioendothelioma
• PubMed - Hemangioendothelioma (28 unread)
• Trial - Hemangioendothelioma (1 unread)

Hepatoblastoma (30 unread)

• Google - Hepatoblastoma (4 unread)
• PubMed - Hepatoblastoma (24 unread)
• Trial - Hepatoblastoma (2 unread)

Pancreas (51 unread)

• Google - Insulinoma (4 unread)
• PubMed - Insulinoma (46 unread)
• Trial - Insulinoma (1 unread)

Phyllodes (17 unread)

• Google - Phyllodes Tumor (4 unread)
• PubMed - Phyllodes Tumor (13 unread)
• Trial - Phyllodes

PMP and Mucinous Tumors (15 unread)

• Google - Pseudomyxoma Peritonei (1 unread)
• PubMed - Pseudomyxoma Peritonei (PMP) (13 unread)
• Trial - Pseudomyxoma Peritonei (1 unread)

Rhabdomyosarcoma (78 unread)

• Google - Rhabdomyosarcoma (9 unread)
• PubMed - Rhabdomyosarcoma (60 unread)
• Trial - Rhabdomyosarcoma (9 unread)

Sarcoma (996 unread)

• Google - Sarcoma (13 unread)
• PubMed - Sarcoma (856 unread)
• Trial - Sarcoma (127 unread)

Trials - Gall Bladder Cancer (11 unread)

• 

  Integrative Medicine for Chemotherapy-Induced Peripheral Neuropathy

  Posted: September 22nd, 2017, 2:00pm GMT

  Condition:   Chemotherapy-induced Peripheral Neuropathy
  Interventions:   Other: Acupuncture;   Other: Multi-modality (Acupuncture "plus")
  Sponsors:   The Chaim Sheba Medical Center;   Bnai Zion Medical Center;   Lin Medical Center, Haifa;   Carmel Medical Center
  Not yet recruiting
• 

  TAS-102 in Treating Advanced Biliary Tract Cancers

  Posted: September 7th, 2017, 2:00pm GMT

  Conditions:   Cholangiocarcinoma;   Stage III Gallbladder Cancer AJCC v7;   Stage IIIA Gallbladder Cancer AJCC v7;   Stage IIIB Gallbladder Cancer AJCC v7;   Stage IV Gallbladder Cancer AJCC v7;   Stage IVA Gallbladder Cancer AJCC v7;   Stage IVB Gallbladder Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Not yet recruiting
• 

  Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

  Posted: August 19th, 2017, 2:00pm GMT

  Conditions:   Extrahepatic Bile Duct Adenocarcinoma, Biliary Type;   Gallbladder Adenocarcinoma, Biliary Type;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Cholangiocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Intrahepatic Cholangiocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Gallbladder Cancer AJCC V7;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage III Intrahepatic Cholangiocarcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Gallbladder Cancer AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Gallbladder Cancer AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Gallbladder Cancer AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Gallbladder Cancer AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7;   Stage IVB Gallbladder Cancer AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7;   Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Carcinoma
  Interventions:   Biological: Durvalumab;   Drug: Guadecitabine
  Sponsors:   University of Southern California;   National Cancer Institute (NCI)
  Not yet recruiting
• 

  Pembrolizumab in Biliary Tract Cancer

  Posted: August 8th, 2017, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Metastatic Cancer;   Advanced Cancer;   Gallbladder Cancer
  Interventions:   Drug: Pembrolizumab;   Drug: Cisplatin;   Drug: Gemcitabine
  Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
  Not yet recruiting - verified August 2017
• 

  Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangio

  Posted: July 25th, 2017, 2:00pm GMT

  Conditions:   Cholangiocarcinoma Non-resectable;   Cholangiocarcinoma, Intrahepatic;   Cholangiocarcinoma, Extrahepatic;   Gallbladder Adenocarcinoma
  Interventions:   Drug: PEGylated Recombinant Human Hyaluronidase;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Atezolizumab
  Sponsor:   Halozyme Therapeutics
  Not yet recruiting
• 

  A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

  Posted: January 23rd, 2017, 3:00pm GMT

  Conditions:   Advanced Cancer;   Metastatic Cancer;   Biliary Tract Carcinoma;   Cholangiocarcinoma;   Gall Bladder Carcinoma;   Solid Tumor;   Non-Hodgkin's Lymphoma
  Interventions:   Drug: Merestinib;   Drug: Cisplatin;   Drug: Gemcitabine
  Sponsor:   Eli Lilly and Company
  Recruiting
• 

  A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

  Posted: October 2nd, 2016, 2:00pm GMT

  Conditions:   Gastrointestinal Cancer;   Neuroendocrine Tumours;   Malignant Female Reproductive System Neoplasm
  Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
  Sponsors:   Olivia Newton-John Cancer Research Institute;   Bristol-Myers Squibb
  Recruiting
• 

  Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

  Posted: October 9th, 2014, 2:00pm GMT

  Conditions:   Breast Cancer;   Colon Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastrointestinal Cancer;   Liver and Intrahepatic Biliary Tract Cancer;   Lung Cancer;   Metastatic Cancer;   Pancreatic Cancer;   Rectal Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
  Interventions:   Procedure: radionuclide imaging;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: Cu 64 anti-CEA monoclonal antibody M5A IV
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• 

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  Posted: June 23rd, 2014, 2:00pm GMT

  Conditions:   Cholangiocarcinoma;   Gall Bladder Carcinoma
  Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Capecitabine
  Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   Deutsche Krebshilfe e.V., Bonn (Germany);   medac GmbH;   Cancer Research UK;   Australasian Gastro Intestinal Trials Group (AGITG);   KWF Kankerbestrijding The Netherlands
  Recruiting
• 

  Single Agent Regorafenib in Refractory Advanced Biliary Cancers

  Posted: April 11th, 2014, 2:00pm GMT

  Condition:   Cancer of the Bile Duct
  Intervention:   Drug: Regorafenib
  Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bayer
  Recruiting - verified August 2017
• 

  Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer

  Posted: May 14th, 2013, 2:00pm GMT

  Conditions:   Cholangiocarcinoma;   Gallbladder Carcinoma;   Biliary Carcinoma
  Intervention:   Drug: Gemcitabine-Pazopanib
  Sponsors:   Hellenic Cooperative Oncology Group;   GlaxoSmithKline
  Recruiting